Skip to main content

Menu

BNFC December 2024 Update

This update contains 2 significant changes, 5 dose changes, 1 new monograph, 1 new preparation, and 2 deleted preparations.

Significant Changes:

  • Dalteparin sodium: update to indications and dosing for treatment and prophylaxis of thromboembolism, and associated monitoring requirements.
  • Urinary-tract infections: updated guidance for the prophylaxis of recurrent urinary tract infections.

Dose Changes:

  • Epipen® auto-injector 0.3 mg (adrenaline/epinephrine) [update to body-weight ranges].
  • Epipen® Jr auto-injector 0.15 mg (adrenaline/epinephrine) [update to body-weight ranges].
  • Jext® 150 micrograms (adrenaline/epinephrine) [update to body-weight ranges].
  • Jext® 300 micrograms (adrenaline/epinephrine) [update to body-weight ranges].
  • Risdiplam [update to dosing and dose expression].

New Monographs:

  • Methenamine Hippurate.

New Preparations:

  • Velariq® [oxybutynin hydrochloride].

Deleted Preparations:

  • Emerade® 300 micrograms [adrenaline/epinephrine].
  • Emerade® 500 micrograms [adrenaline/epinephrine].